MetaVia Inc. MTVA 深 滬
等待開盤 05-19 09:30:00 美东时间
1.11
0.000
0.00%
華盛通- 最 高1.135
- 今 開1.10
- 成交量 5.27万股
- 最 低 1.0804
- 昨 收 1.11
- 總市值 573.25万
- 52周最高 19.0289
- 市盈率 靜 --
- 換手率 1.02%
- 52周最低 0.9661
- 委 比 77.84%
- 總股本 516.44万
- 歷史最高 1527900.00
- 量 比 0.41
- 振 幅 4.92%
- 歷史最低 0.9661
- 每 手 1
- 風險率 3.59%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 花旗上调英特尔目标价至130美元；大摩上调英伟达目标价至285美元；National 、Yesway获多家大行首予买入评级
今日重点评级关注：TD Cowen：维持Strive"买入"评级，目标价从28美元升至30美元；蒙特利尔银行：维持KinderCare Learning"跑赢大市"评级，目标价从4美元升至6美元
今天 10:55
MetaVia Showcases Key Cardiometabolic Data at ADA 2026
MetaVia ( ($MTVA) ) just unveiled an update. MetaVia Inc., a clinical-stage bio...
05-18 22:04
HC Wainwright & Co. Reiterates Buy on MetaVia, Maintains $20 Price Target
HC Wainwright & Co. analyst Andrew S. Fein reiterates MetaVia (NASDAQ:MTVA) with a Buy and maintains $20 price target.
05-18 21:56
MetaVia Q1 EPS $(0.79) Misses $(0.74) Estimate
MetaVia (NASDAQ:MTVA) reported quarterly losses of $(0.79) per share which missed the analyst consensus estimate of $(0.74) by 6.76 percent. This is a 80.05 percent increase over losses of $(3.96) per share from the same
05-15 04:48
MetaVia To Present Obesity Drug DA-1726 Data At EASL Congress 2026 In Barcelona
MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that a late-breaking abstract highlighting DA-1726, a novel dual oxyntomodulin (OXM)
05-11 20:35
MetaVia Says First Patient Dosed In Part 3 Of Phase 1 Clinical Trial Evaluating DA-1726, Dual Oxyntomodulin Analog Targeting Both GLP-1 And Glucagon Receptors
16-Week Study Evaluates One-Step Dose Titration to 48 mg and Two-Step Dose Titration to 64 mg in Obese Otherwise Healthy AdultsCAMBRIDGE, Mass., April 10, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage
04-10 20:35
美股大行评级 | 能源股再或大行青睐！康菲石油、雪铁龙、埃克森美孚、响尾蛇能源等获上调目标价；Unity评级分歧大，大摩、美银上调，富国银行下调
今日重点评级关注：花旗：维持Biomea Fusion"买入"评级，目标价从6美元升至7美元；Chardan Capital：维持Hyperion DeFi"买入"评级，目标价从7.75美元升至8.25美元
03-30 11:49
HC Wainwright & Co. Maintains Buy on MetaVia, Lowers Price Target to $20
HC Wainwright & Co. analyst Andrew S. Fein maintains MetaVia (NASDAQ:MTVA) with a Buy and lowers the price target from $40 to $20.
03-28 00:27
MetaVia Q4 EPS $(0.42) Beats $(1.73) Estimate
MetaVia (NASDAQ:MTVA) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(1.73) by 75.69 percent. This is a 88.07 percent increase over losses of $(3.52) per share from the same
03-26 20:37
MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update
48 mg Phase 1 Data Demonstrate Potential Best-in-Class Profile for DA-1726 with 9.1% Weight Loss, Improved Glucose Control and Direct Liver Benefit Planned Phase 1 Part 3 16-Week Titration S...
03-26 20:31
